Y-mAbs Therapeutics (YMAB) Stock Forecast, Price Target & Predictions
YMAB Stock Forecast
Y-mAbs Therapeutics stock forecast is as follows: an average price target of $20.50 (represents a 50.62% upside from YMAB’s last price of $13.61) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
YMAB Price Target
The average price target for Y-mAbs Therapeutics (YMAB) is $20.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $13.00. This represents a potential 50.62% upside from YMAB's last price of $13.61.
YMAB Analyst Ratings
According to 6 Wall Street analysts, Y-mAbs Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for YMAB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Y-mAbs Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Nicole Germino | Truist Financial | $21.00 | $12.33 | 70.32% | 54.30% |
| May 10, 2024 | Robert Burns | H.C. Wainwright | $22.00 | $12.87 | 70.94% | 61.65% |
| Apr 05, 2024 | Etzer Darout | BMO Capital | $26.00 | $14.56 | 78.57% | 91.04% |
| May 10, 2023 | YMAB)to Outperform | Wedbush | $13.00 | $9.89 | 31.38% | -4.48% |
The latest Y-mAbs Therapeutics stock forecast, released on Jun 28, 2024 by Nicole Germino from Truist Financial, set a price target of $21.00, which represents a 70.32% increase from the stock price at the time of the forecast ($12.33), and a 54.30% increase from YMAB last price ($13.61).
Y-mAbs Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $21.00 | $23.00 |
| Last Closing Price | $13.61 | $13.61 | $13.61 |
| Upside/Downside | -100.00% | 54.30% | 68.99% |
In the current month, the average price target of Y-mAbs Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Y-mAbs Therapeutics's last price of $13.61. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Sep 09, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 16, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Aug 13, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 13, 2024 | BMO Capital | Underperform | Underperform | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 05, 2024 | BMO Capital | Outperform | Outperform | Hold |
| May 10, 2023 | Wedbush | - | Outperform | Upgrade |
| Jan 05, 2023 | Cowen & Co. | - | Market Perform | Downgrade |
| Oct 31, 2022 | Guggenheim | Buy | Buy | Hold |
Y-mAbs Therapeutics's last stock rating was published by Cantor Fitzgerald on Sep 09, 2024. The company gave YMAB a "Underperform" rating, the same as its previous rate.
Y-mAbs Therapeutics Financial Forecast
Y-mAbs Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $23.36M | $20.45M | $20.75M | $20.25M | $31.45M | $12.54M | - | $10.49M | $9.60M | $8.96M | $10.95M | $5.38M | $20.75M |
| Avg Forecast | $27.96M | $27.50M | $26.68M | $25.29M | $25.46M | $23.82M | $23.02M | $22.21M | $20.95M | $20.97M | $20.33M | $15.58M | $20.35M | $12.01M | $11.23M | $10.90M | $10.77M | $10.87M | $7.33M | $41.84M | $11.59M |
| High Forecast | $29.82M | $29.34M | $28.46M | $26.98M | $27.16M | $24.94M | $24.56M | $23.69M | $22.15M | $22.37M | $21.69M | $16.62M | $21.71M | $12.82M | $11.23M | $11.26M | $11.13M | $11.23M | $7.57M | $43.21M | $11.97M |
| Low Forecast | $26.00M | $25.58M | $24.81M | $23.51M | $23.68M | $22.18M | $21.40M | $20.65M | $19.60M | $19.50M | $18.90M | $14.49M | $18.92M | $11.17M | $11.23M | $10.72M | $10.59M | $10.69M | $7.20M | $41.14M | $11.40M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.12% | 0.98% | 1.02% | 1.30% | 1.55% | 1.04% | - | 0.96% | 0.89% | 0.82% | 1.49% | 0.13% | 1.79% |
Y-mAbs Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $22.21M, with a low forecast of $20.65M, and a high forecast of $23.69M. YMAB's average Quarter revenue forecast represents a -4.95% decrease compared to the company's last Quarter revenue of $23.36M (Dec 23).
Y-mAbs Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-74.00K | $-7.75M | $-7.22M | $-7.50M | $-1.15M | $-25.79M | - | $-27.50M | $-35.47M | $-28.56M | $-22.50M | $33.88M | $-19.82M |
| Avg Forecast | $-12.53M | $-12.33M | $-11.96M | $-11.33M | $-11.41M | $-10.68M | $-10.32M | $-37.05M | $-9.39M | $-9.40M | $-9.11M | $-33.68M | $-9.12M | $-28.27M | $-5.03M | $-30.62M | $-27.87M | $-25.70M | $-27.46M | $-18.76M | $-20.98M |
| High Forecast | $-11.65M | $-11.46M | $-11.12M | $-10.54M | $-10.61M | $-9.94M | $-9.59M | $-29.64M | $-8.78M | $-8.74M | $-8.47M | $-26.95M | $-8.48M | $-22.62M | $-5.03M | $-24.50M | $-22.29M | $-20.56M | $-21.97M | $-18.44M | $-16.79M |
| Low Forecast | $-13.37M | $-13.15M | $-12.76M | $-12.09M | $-12.17M | $-11.18M | $-11.01M | $-44.46M | $-9.93M | $-10.03M | $-9.72M | $-40.42M | $-9.73M | $-33.93M | $-5.03M | $-36.75M | $-33.44M | $-30.84M | $-32.95M | $-19.37M | $-25.18M |
| Surprise % | - | - | - | - | - | - | - | - | 0.01% | 0.82% | 0.79% | 0.22% | 0.13% | 0.91% | - | 0.90% | 1.27% | 1.11% | 0.82% | -1.81% | 0.94% |
2 analysts predict YMAB's average Quarter EBITDA for Jun 21 to be $-27.46M, with a high of $-21.97M and a low of $-32.95M. This is -181.04% lower than Y-mAbs Therapeutics's previous annual EBITDA (Mar 21) of $33.88M.
Y-mAbs Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-2.28M | $-7.75M | $-6.30M | $-5.10M | $-401.00K | $-29.04M | - | $-28.44M | $-38.03M | $-28.86M | $-22.94M | $33.41M | $-19.93M |
| Avg Forecast | $-6.65M | $-6.39M | $-7.17M | $-6.33M | $-5.04M | $-6.56M | $-5.47M | $-37.31M | $-8.63M | $-8.27M | $-10.65M | $-33.92M | $-20.09M | $-28.57M | $-29.14M | $-30.84M | $-28.99M | $-25.97M | $-28.00M | $58.56M | $-21.11M |
| High Forecast | $-6.04M | $-5.81M | $-6.52M | $-5.75M | $-4.58M | $-5.25M | $-4.97M | $-29.85M | $-7.27M | $-7.51M | $-9.68M | $-27.14M | $-18.25M | $-22.86M | $-29.14M | $-24.67M | $-23.19M | $-20.78M | $-22.40M | $70.27M | $-16.88M |
| Low Forecast | $-7.23M | $-6.94M | $-7.79M | $-6.88M | $-5.48M | $-9.84M | $-5.95M | $-44.77M | $-9.08M | $-8.98M | $-11.58M | $-40.70M | $-21.83M | $-34.28M | $-29.14M | $-37.00M | $-34.78M | $-31.17M | $-33.60M | $46.85M | $-25.33M |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | 0.94% | 0.59% | 0.15% | 0.02% | 1.02% | - | 0.92% | 1.31% | 1.11% | 0.82% | 0.57% | 0.94% |
Y-mAbs Therapeutics's average Quarter net income forecast for Jun 21 is $-28.00M, with a range of $-33.60M to $-22.40M. YMAB's average Quarter net income forecast represents a -183.79% decrease compared to the company's last Quarter net income of $33.41M (Mar 21).
Y-mAbs Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $11.13M | $10.20M | $11.27M | $12.25M | $10.79M | $13.63M | - | $13.44M | $15.14M | $13.99M | $13.47M | $11.97M | $14.63M |
| Avg Forecast | $34.51M | $33.95M | $32.93M | $31.21M | $31.43M | $29.40M | $28.41M | $17.86M | $25.86M | $25.89M | $25.09M | $19.23M | $25.12M | $14.83M | $13.86M | $13.45M | $13.30M | $13.42M | $9.04M | $20.98M | $14.31M |
| High Forecast | $36.81M | $36.21M | $35.13M | $33.29M | $33.52M | $30.79M | $30.31M | $21.44M | $27.34M | $27.61M | $26.77M | $20.51M | $26.79M | $15.82M | $13.86M | $13.89M | $13.73M | $13.86M | $9.34M | $25.17M | $14.77M |
| Low Forecast | $32.09M | $31.57M | $30.62M | $29.02M | $29.22M | $27.38M | $26.42M | $14.29M | $24.19M | $24.07M | $23.33M | $17.88M | $23.35M | $13.79M | $13.86M | $13.23M | $13.07M | $13.19M | $8.89M | $16.78M | $14.07M |
| Surprise % | - | - | - | - | - | - | - | - | 0.43% | 0.39% | 0.45% | 0.64% | 0.43% | 0.92% | - | 1.00% | 1.14% | 1.04% | 1.49% | 0.57% | 1.02% |
Y-mAbs Therapeutics's average Quarter SG&A projection for Mar 24 is $17.86M, based on 2 Wall Street analysts, with a range of $14.29M to $21.44M. The forecast indicates a 60.42% rise compared to YMAB last annual SG&A of $11.13M (Dec 23).
Y-mAbs Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.14 | $-0.12 | $-0.01 | $-0.66 | - | $-0.65 | $-0.87 | $-0.66 | $-0.53 | $0.80 | $-0.48 |
| Avg Forecast | $-0.15 | $-0.15 | $-0.16 | $-0.14 | $-0.11 | $-0.15 | $-0.12 | $-0.14 | $-0.20 | $-0.19 | $-0.24 | $-0.32 | $-0.46 | $-0.71 | $-0.67 | $-0.72 | $-0.69 | $-0.58 | $-0.66 | $0.39 | $-0.47 |
| High Forecast | $-0.14 | $-0.13 | $-0.15 | $-0.13 | $-0.10 | $-0.12 | $-0.11 | $-0.12 | $-0.17 | $-0.17 | $-0.22 | $-0.29 | $-0.41 | $-0.65 | $-0.67 | $-0.70 | $-0.68 | $-0.57 | $-0.65 | $0.40 | $-0.46 |
| Low Forecast | $-0.16 | $-0.16 | $-0.18 | $-0.16 | $-0.12 | $-0.22 | $-0.14 | $-0.15 | $-0.21 | $-0.20 | $-0.26 | $-0.35 | $-0.50 | $-0.77 | $-0.67 | $-0.75 | $-0.72 | $-0.61 | $-0.69 | $0.38 | $-0.49 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.58% | 0.38% | 0.02% | 0.93% | - | 0.91% | 1.26% | 1.13% | 0.80% | 2.07% | 1.02% |
According to 2 Wall Street analysts, Y-mAbs Therapeutics's projected average Quarter EPS for Jun 21 is $-0.66, with a low estimate of $-0.69 and a high estimate of $-0.65. This represents a -182.92% decrease compared to YMAB previous annual EPS of $0.80 (Mar 21).
Y-mAbs Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| BLUE | bluebird bio | $0.50 | $14.13 | 2726.00% | Hold |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| KRON | Kronos Bio | $0.92 | $7.63 | 729.35% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $4.16 | $21.86 | 425.48% | Buy |
| BDTX | Black Diamond Therapeutics | $4.73 | $14.75 | 211.84% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.40 | $31.00 | 198.08% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.79 | $38.80 | 181.36% | Buy |
| STRO | Sutro Biopharma | $3.95 | $10.80 | 173.42% | Buy |
| EWTX | Edgewise Therapeutics | $19.07 | $48.00 | 151.70% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| LRMR | Larimar Therapeutics | $6.85 | $14.50 | 111.68% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.00 | $36.00 | 100.00% | Buy |
| CCCC | C4 Therapeutics | $6.38 | $11.33 | 77.59% | Hold |
| MRUS | Merus | $49.42 | $77.86 | 57.55% | Buy |
| YMAB | Y-mAbs Therapeutics | $13.57 | $20.50 | 51.07% | Buy |
| TVTX | Travere Therapeutics | $14.35 | $21.60 | 50.52% | Buy |
| MIRM | Mirum Pharmaceuticals | $37.90 | $54.50 | 43.80% | Buy |
| MRSN | Mersana Therapeutics | $2.12 | $3.00 | 41.51% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $44.06 | $52.17 | 18.41% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| PCVX | Vaxcyte | $116.54 | $124.14 | 6.52% | Buy |
YMAB Forecast FAQ
Is Y-mAbs Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Y-mAbs Therapeutics (YMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of YMAB's total ratings.
What is YMAB's price target?
Y-mAbs Therapeutics (YMAB) average price target is $20.5 with a range of $13 to $26, implying a 50.62% from its last price of $13.61. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Y-mAbs Therapeutics stock go up soon?
According to Wall Street analysts' prediction for YMAB stock, the company can go up by 50.62% (from the last price of $13.61 to the average price target of $20.5), up by 91.04% based on the highest stock price target, and down by -4.48% based on the lowest stock price target.
Can Y-mAbs Therapeutics stock reach $20?
YMAB's average twelve months analyst stock price target of $20.5 supports the claim that Y-mAbs Therapeutics can reach $20 in the near future.
What are Y-mAbs Therapeutics's analysts' financial forecasts?
Y-mAbs Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $94.51M (high $100.35M, low $87.91M), average EBITDA is $-69.459M (high $-59.791M, low $-78.824M), average net income is $-54.387M (high $-44.654M, low $-66.043M), average SG&A $107.1M (high $116.06M, low $97.31M), and average EPS is $-0.524 (high $-0.46, low $-0.631). YMAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $107.43M (high $114.6M, low $99.89M), average EBITDA is $-48.152M (high $-44.775M, low $-51.368M), average net income is $-26.542M (high $-24.122M, low $-28.846M), average SG&A $132.59M (high $141.45M, low $123.29M), and average EPS is $-0.603 (high $-0.548, low $-0.655).
Did the YMAB's actual financial results beat the analysts' financial forecasts?
Based on Y-mAbs Therapeutics's last annual report (Dec 2023), the company's revenue was $84.82M, beating the average analysts forecast of $77.83M by 8.98%. Apple's EBITDA was $-25.672M, missing the average prediction of $-61.586M by -58.32%. The company's net income was $-21.427M, missing the average estimation of $-61.467M by -65.14%. Apple's SG&A was $44.86M, missing the average forecast of $96.06M by -53.30%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.945 by -99.95%. In terms of the last quarterly report (Dec 2023), Y-mAbs Therapeutics's revenue was $23.36M, beating the average analysts' forecast of $20.95M by 11.53%. The company's EBITDA was $-74K, missing the average prediction of $-9.39M by -99.21%. Y-mAbs Therapeutics's net income was $-2.281M, missing the average estimation of $-8.628M by -73.56%. The company's SG&A was $11.14M, missing the average forecast of $25.86M by -56.93%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.196 by -99.95%